Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2b clinical study of Teverelix, a long-acting …
FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients Read More
PHILADELPHIA, PA — Medicus Pharma (NASDAQ: MDCX) has reworked the economics of its lead urology and oncology program, cutting royalty obligations tied to Teverelix in half while preserving full global …
Medicus Slashes Teverelix Royalty, Sharpens Path to $6B Market Opportunity Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) marked its first anniversary as a publicly traded company on Thursday by ringing the Nasdaq Opening Bell at the Nasdaq MarketSite in …
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said detailed clinical data from early-stage studies of its long-acting hormone-suppressing drug Teverelix have been accepted for presentation at a major international …
Medicus Gene-Blocking Drug Shows Fast Hormone Control Ahead of Key Endocrine Meet Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has completed U.S. enrollment for a Phase 2 clinical study testing a needle-free treatment for a common form of skin …
Medicus Fills Phase 2 Trial, Eyes FDA Talks for Needle-Free Skin Cancer Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) named President Carolyn Bonner as its new chief financial officer, formalizing a role she has held on an interim basis since September …
Medicus Pharma Elevates President Carolyn Bonner to CFO as Clinical Pipeline Accelerates Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) announced a major leadership transition Monday, elevating President Carolyn Bonner to Chief Financial Officer as the company continues advancing a slate of …
Medicus Pharma Shakes Up Executive Ranks as President Takes on CFO Role Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a federal priority-review request for its investigational SkinJect microneedle patch, a dissolvable doxorubicin-based therapy designed to non-invasively treat basal cell …
Skin Cancer Breakthrough? Pharma Firm Seeks Fast-Track FDA Voucher for Novel Patch Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has entered a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, its investigational doxorubicin-containing microneedle therapy …
Medicus Pharma Partners With Gorlin Syndrome Alliance to Expand Access to SKINJECT Read More